H. Roger Lijnen
#132,130
Most Influential Person Now
H. Roger Lijnen's AcademicInfluence.com Rankings
H. Roger Lijnenbiology Degrees
Biology
#8798
World Rank
#11930
Historical Rank
Molecular Biology
#1144
World Rank
#1170
Historical Rank
Biochemistry
#1300
World Rank
#1420
Historical Rank

Download Badge
Chemistry Biology
Why Is H. Roger Lijnen Influential?
(Suggest an Edit or Addition)H. Roger Lijnen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. (1982) (1286)
- Persistence of Atherosclerotic Plaque but Reduced Aneurysm Formation in Mice With Stromelysin-1 (MMP-3) Gene Inactivation (2001) (249)
- On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. (1979) (249)
- Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. (1980) (246)
- Studies on the mechanism of the antifibrinolytic action of tranexamic acid. (1981) (219)
- Angiogenesis and development of adipose tissue (2010) (213)
- Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. (1999) (211)
- Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Gene (2002) (210)
- On the mechanism of fibrin-specific plasminogen activation by staphylokinase. (1991) (195)
- Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. (1983) (194)
- Mechanisms of physiological fibrinolysis. (1995) (182)
- Activation of plasminogen by pro-urokinase. I. Mechanism. (1986) (182)
- Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. (1984) (175)
- Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. (1986) (173)
- Matrix Metalloproteinases and Cellular Fibrinolytic Activity (2004) (163)
- Strategies for the Improvement of Thrombolytic Agents (1991) (160)
- Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – I. Fibrinolytic and Fibrinogenolytic Properties in Human Plasma In Vitro of Urokinases Obtained from Human Urine or by Recombinant DNA Technology (1984) (151)
- Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. (1984) (148)
- Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). (1987) (142)
- Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? (1994) (140)
- Matrix Metalloproteinase System Deficiencies and Matrix Degradation (1999) (134)
- Tissue‐type plasminogen activator: a historical perspective and personal account (2004) (134)
- Basic and clinical aspects of fibrinolysis and thrombolysis. (1991) (132)
- Effect of Retraction on the Lysis of Human Clots with Fibrin Specific and Non-Fibrin Specific Plasminogen Activators (1989) (123)
- Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. (1999) (119)
- Endothelium in hemostasis and thrombosis. (1997) (117)
- Activation of plasminogen by pro-urokinase. II. Kinetics. (1986) (117)
- Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. (1987) (113)
- Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. (1982) (107)
- Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin. (1979) (104)
- Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. (1986) (104)
- The tissue-type plasminogen activator story. (2009) (101)
- Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu). (1990) (101)
- Characterization of the murine plasma fibrinolytic system. (1994) (101)
- On the mechanism of the activation of human plasminogen by recombinant staphylokinase. (1993) (98)
- Tissue-type plasminogen activator, a new prognostic marker in breast cancer. (1988) (95)
- Molecular Basis of Fibrinolysis, as Relevant for Thrombolytic Therapy (1995) (93)
- Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. (2009) (91)
- The fibrinolytic system in man. (1986) (90)
- Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. (1986) (89)
- Mouse Carotid Artery Ligation Induces Platelet-Leukocyte–Dependent Luminal Fibrin, Required for Neointima Development (2001) (87)
- A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. (1985) (85)
- Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). (1998) (83)
- The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. (1989) (82)
- Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. (2005) (81)
- Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis (1989) (78)
- Dysfibrinogenemia (Fibrinogen Dusard) Associated with Impaired Fibrin-Enhanced Plasminogen Activation (1984) (78)
- Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. (1987) (77)
- Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. (1987) (76)
- Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – II. Turnover of Natural and Recombinant Urokinase in Rabbits and Squirrel Monkeys (1984) (76)
- A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. (2005) (75)
- Effect of matrix metalloproteinase inhibition on adipose tissue development. (2005) (71)
- On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice (2005) (68)
- Adipose Tissue and Atherothrombosis (2003) (68)
- Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. (1988) (68)
- Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. (1986) (67)
- Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. (1996) (65)
- Characterization of the interaction between plasminogen and staphylokinase. (1994) (65)
- Isolation and characterisation of natural and recombinant staphylokinase (1992) (65)
- Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. (2000) (64)
- Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. (1993) (63)
- Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin. (1987) (63)
- Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones. (1984) (62)
- Correlation between Progressive Adsorption of Plasminogen to Blood Clots and Their Sensitivity to Lysis (1990) (61)
- Comparative Fibrinolytic Properties of Staphylokinase and Streptokinase in Animal Models of Venous Thrombosis (1991) (61)
- On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha 2-antiplasmin and fibrin. (1981) (61)
- Multiple forms of plasminogen activator in human breast tumors. (1985) (60)
- Matrix Metalloproteinase-9 Deficiency Impairs Host Defense against Abdominal Sepsis1 (2006) (59)
- Interactions between Staphylokinase, Plasmin(ogen), and Fibrin (1996) (59)
- Effects of plasminogen activator inhibitor‐1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice (2005) (59)
- Absence of Synergism Between Tissue-Type Plasminogen Activator (t-PA), Single-Chain UrokinaseType Plasminogen Activator (scu-PA) and Urokinase on Clot Lysis in a Plasma Milieu In Vitro (1986) (58)
- Endogenous Tissue-Type Plasminogen Activator Is Protective during Escherichia coli-Induced Abdominal Sepsis in Mice1 (2006) (58)
- Fibrinolytic Agents: Mechanisms of Activity and Pharmacology (1995) (57)
- Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity (2012) (56)
- Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface. (1993) (54)
- Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue‐Type and Urokinase‐Type Plasminogen Activators (1991) (53)
- Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies. (1986) (52)
- Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. (1993) (52)
- Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-α, TNF-α converting enzyme and ADAMTS family members in murine fat territories (2003) (51)
- Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. (1991) (50)
- Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. (1989) (50)
- Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin (1989) (49)
- Mechanisms of plasminogen activation (1994) (48)
- Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems (2000) (48)
- Histidine-rich glycoprotein in a normal and a clinical population. (1981) (48)
- A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents (1990) (47)
- Kinetic properties of tripeptide lysyl chloromethyl ketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases. (1980) (47)
- Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques (2006) (46)
- Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. (1987) (46)
- Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin. (1993) (45)
- Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. (1993) (44)
- On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin-formula> and fibrin (1992) (44)
- Biochemical-properties of natural and recombinant staphylokinase (1992) (44)
- Physicochemical, immunochemical and functional comparison of human histidine-rich glycoprotein and autorosette inhibition factor. (1983) (43)
- Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue (2006) (43)
- Structural domains of streptokinase involved in the interaction with plasminogen. (1995) (43)
- Impaired fibrinolysis and the risk for coronary heart disease. (1996) (42)
- Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – IV. Variability in Fibrinolytic Response of Plasma of Several Mammalian Species (1984) (41)
- Impaired Adipose Tissue Development in Mice With Inactivation of Placental Growth Factor Function (2006) (41)
- New approaches to thrombolytic therapy. (1984) (41)
- Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. (1989) (41)
- Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties. (1987) (40)
- Pathophysiology of the plasminogen/plasmin system (1996) (39)
- Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura (2010) (39)
- Structural and Functional Basis of Plasminogen Activation by Staphylokinase (1999) (39)
- Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. (1990) (39)
- Amino‐acid sequence of human α2‐antiplasmin (1987) (37)
- Characterization and Targeting of the Murine α2-Antiplasmin Gene (1997) (37)
- Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26. (1994) (37)
- Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro (1992) (36)
- Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase. (1984) (36)
- Increased Angiostatin Levels in Bronchoalveolar Lavage Fluids from ARDS Patients and from Human Volunteers after Lung Instillation of Endotoxin (2002) (35)
- Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. (1991) (34)
- Interaction of staphylokinase with different molecular forms of plasminogen. (1993) (34)
- Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. (1986) (33)
- Histidine-Rich Glycoprotein Modulates the Anticoagulant Activity of Heparin in Human Plasma (1984) (33)
- In Vitro Fibrinolytic Activity of Recombinant Tissue-Type Plasminogen Activator in the Plasma of Various Primate Species (1984) (33)
- Influence of t-PA and u-PA on Adipose Tissue Development in a Murine Model of Diet-Induced Obesity (2002) (33)
- Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro. (1984) (33)
- Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator. (1987) (32)
- A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. (1990) (30)
- Mechanisms of plasminogen activation by mammalian plasminogen activators. (1988) (30)
- Tissue-type plasminogen activator. Mechanisms of action and thrombolytic properties. (1986) (30)
- Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. (1988) (30)
- Interaction of Heparin with Histidine-Rich Glycoprotein and with Antithrombin III (1983) (30)
- Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator. (1986) (30)
- Thrombolytic and Pharmacokinetic Properties of Human Tissue-Type Plasminogen Activator Variants, Obtained by Deletion and/or Duplication of Structural/Functional Domains, in a Hamster Pulmonary Embolism Model (1991) (29)
- Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog. (1992) (29)
- Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin‐induced cell detachment and apoptosis (2005) (29)
- Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma. (1993) (29)
- Role of Active Center and Lysine Binding Sites of Plasmin in Plasmin-Induced Platelet Activation and Disaggregation (1991) (29)
- Effect of Fibrin-Like Stimulators on the Activation of Plasminogen by Tissue-Type Plasminogen Activator (t-PA) - Studies with Active Site Mutagenized Plasminogen and Plasmin Resistant t-PA (1990) (29)
- Age-associated adaptations in murine adipose tissues. (2010) (28)
- On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator. (1991) (28)
- In vitro prothrombin synthesis from a purified precursor protein. III. Preparation of an acid-soluble substrate for vitamin K-dependent carboxylase by limited proteolysis of bovine descarboxyprothrombin. (1981) (28)
- Obesity promotes injury induced femoral artery thrombosis in mice. (2008) (27)
- Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993) (1994) (26)
- Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains. (1990) (26)
- Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor‐1 (PAI‐1) (2004) (26)
- Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase (1992) (26)
- Enhanced Fibrinolytic Potential in Mice with Combined Homozygous Deficiency of α2-antiplasmin and PAI-1 (2001) (26)
- A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. (1986) (26)
- Neutralization of heparin activity by binding to human histidine-rich glycoprotein. (1983) (26)
- Adverse adipose phenotype and hyperinsulinemia in gravid mice deficient in placental growth factor. (2008) (26)
- Fibrin‐specific Fibrinolysis (1992) (26)
- Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy. (1981) (25)
- Role of plasminogen activation in neuronal organization and survival (2009) (25)
- Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. (1994) (24)
- Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. (2012) (23)
- Enhancement of Clot Lysis In Vitro and In Vivo with a Bispecific Monoclonal Antibody Directed against Human Fibrin and against Urokinase-Type Plasminogen Activator (1991) (23)
- Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin. (1992) (23)
- Characterization of Domain Deletion and/or Duplication Mutants of a Recombinant Chimera of Tissue-Type Plasminogen Activator and Urokinase-Type Plasminogen Activator (rt-PA/u-PAI) (1990) (23)
- Influence of membrane‐bound tumor necrosis factor (TNF)‐α on obesity and glucose metabolism (2004) (23)
- Towards better thrombolytic therapy. (1991) (22)
- Modulation of Cell-associated Plasminogen Activation by Stromelysin-1 (MMP-3) (1999) (22)
- Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface. (1999) (22)
- Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen (1996) (22)
- Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator. (1988) (21)
- Macrophage elastase (MMP-12) in expanding murine adipose tissue. (2013) (21)
- Role of α2-Antiplasmin in Fibrin-Specific Clot Lysis with Single-Chain Urokinase-Type Plasminogen Activator in Human Plasma (1991) (20)
- Small Animal Thrombosis Models for the Evaluation of Thrombolytic Agents (1991) (20)
- α2-Antiplasmin Gene Deficiency in Mice Does Not Affect Neointima Formation After Vascular Injury (2000) (20)
- Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. (1992) (19)
- Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity. (2001) (19)
- Effect of gelatinase inhibition on adipogenesis and adipose tissue development (2012) (19)
- Staphylokinase, a fibrin-specific bacterial plasminogen activator (1996) (19)
- Differential reactivity of Glu-Gly-Arg-CH2Cl, a synthetic urokinase inhibitor, with single-chain and two-chain forms of urokinase-type plasminogen activator. (1987) (19)
- Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons (1992) (19)
- Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. (2011) (18)
- Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains. (1990) (18)
- Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential. (1995) (18)
- Effect of premature aging on murine adipose tissue (2012) (17)
- On the future of thrombolytic therapy for acute myocardial infarction. (1993) (17)
- Molecular mechanisms of thrombolytic therapy. (1986) (17)
- Role of Thrombospondin‐2 in Murine Adipose Tissue Angiogenesis and Development (2012) (17)
- Procoagulant Properties of Intravenous Staphylokinase Versus Tissue-Type Plasminogen Activator (1996) (17)
- Molecular interactions between tissue-type plasminogen activator and plasminogen. (1993) (16)
- Partial Primary Structure of Human α2-Antiplasmin – Homology with Other Plasma Protease Inhibitors (1982) (16)
- Protease inhibitors of human plasma. Alpha-2-antiplasmin. (1985) (16)
- Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex. (1998) (16)
- Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice (2009) (15)
- Recent developments in thrombolytic therapy (2000) (15)
- Comparative Study of the Activity of High and Low Molecular Weight Urokinase in the Presence of Fibrin (1982) (15)
- Proteolytic enzymes in coagulation, fibrinolysis, and complement activation. Introduction. (1993) (15)
- Deficiency of Bmal1 disrupts the diurnal rhythm of haemostasis (2019) (14)
- Characterization of the high-affinity interaction between human plasminogen and pro-urokinase. (1985) (14)
- Tissue-type Plasminogen Activator (tPA) Interacts with Urokinase-type Plasminogen Activator (uPA) via tPA's Lysine Binding Site (1995) (14)
- Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model. (1991) (14)
- On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin. (1992) (14)
- Effect of Standard and Low-Molecular Weight Heparin Fractions on Fibrinolysis and Platelet Aggregation in Patients Undergoing Hysterectomy (1986) (13)
- Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator. (2000) (13)
- Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3). (2001) (12)
- Properties of staphylokinase and its potential as a thrombolytic agent (1995) (12)
- Importance of the interaction between plasminogen and fibrin for plasminogen activation by tissue-type plasminogen activator. (1984) (12)
- Characterisation of a chemical conjugate between a low molecular weight form of recombinant single chain urokinase-type plasminogen activator (comprising Leu144 through Leu411) and F(ab′)2-fragments of a fibrin D-dimer-specific monoclonal antibody (1990) (12)
- Molecular mechanisms of thrombolysis: implications for therapy. (1990) (12)
- Biochemical and Biological Properties of a Recombinant Tissue-Type Plasminogen Activator Derived from the Rat JMI-229 Cell Line (1992) (12)
- Matrix metalloproteinase inhibition affects adipose tissue mass in obese mice (2012) (12)
- Effect of fumagillin on adipocyte differentiation and adipogenesis. (2010) (11)
- Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase. (1992) (11)
- Characterisation of a mutant of recombinant human single chain urokinase-type plasminogen activator (scu-PA), obtained by substitution of arginine 156 and lysine 158 with threonine (1988) (11)
- New strategies in the development of thrombolytic agents. (1988) (11)
- Plasminogen/plasmin system function in mice deficient in stromelysin-1 (MMP-3) or in tissue inhibitor of metalloproteinases type-1 (TIMP-1) (1998) (11)
- Degradation of the apoprotein A-I polypeptide chain of human high density lipoprotein by human plasmin. (1981) (11)
- Plasminogen/plasmin and matrix metalloproteinase system function in mice with targeted inactivation of stromelysin-3 (MMP-11) (1998) (10)
- Molecular Conversions of Recombinant Staphylokinase During Plasminogen Activation in Purified Systems and in Human Plasma (1993) (10)
- Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers. (2009) (10)
- Enzymatic properties of phage-displayed fragments of human plasminogen. (1997) (10)
- Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator. (1988) (10)
- Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin (1990) (9)
- A monoclonal antibody directed against an epitope in the NH2-terminal region of native human plasminogen induces a modification of its functional properties (1997) (9)
- On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen. (1990) (9)
- Molecular mechanism of fibrinolysis. (1984) (9)
- Tissue-type plasminogen activator: mutants, variants, and adjunctive treatment. (1989) (9)
- Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase. (1992) (9)
- Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis (2010) (9)
- Kinetics Of Plasminogen Activation By Tissue Plasminogen Activator. Role Of Fibrin (1981) (8)
- Turnover of histidine-rich glycoprotein during heparin administration in man. (1983) (8)
- Screening panels of monoclonal antibodies using phage-displayed antigen. (1997) (8)
- Interactions of Staphylokinase with Human Platelets (1995) (8)
- Differential Inhibition with Antifibrinolytic Agents of Staphylokinase and Streptokinase Induced Clot Lysis (1995) (8)
- Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator. (1992) (8)
- A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis. (1986) (8)
- Binding of streptokinase and staphylokinase to plasminogen (1995) (8)
- Expression and Characterization of Clustered Charge-to-Alanine Mutants of Low Mr Single-Chain Urokinase-Type Plasminogen Activator (1994) (7)
- Recommendations for the nomenclature of mutant fibrinolytic genes and their proteins. Report of the SSC Fibrinolysis Subcommittee 1990. (1990) (7)
- Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator. (1990) (7)
- TOWARDS THE DEVELOPMENT OF IMPKOVED THROMBOLYTIC AGENTS (1991) (7)
- Development of thrombolytic agents. (1993) (7)
- Amino-acid sequence of human alpha 2-antiplasmin. (1987) (6)
- Thrombolysis with Bolus Injections and Infusions of Tissue-type Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis (1991) (6)
- On the role of placental growth factor in murine adipogenesis. (2007) (6)
- Plasminogen Binding Properties of Macrophage Inflammatory Protein (MIP)-2α (2000) (6)
- Kinetics of the Inhibition of Plasmin in Acidified Human Plasma (1982) (6)
- The reaction of azide with Limulus polyphemus methaemocyanin (1978) (6)
- Amino-acid sequence of human a2-antiplasmin (1987) (6)
- Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala. (1992) (5)
- Primary Structure of Human a2-Antiplasmin, a Serine Protease Inhibitor (Serpin)* (2001) (5)
- Pharmacokinetic properties of mutants of recombinant single chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160 (1990) (5)
- Remaining Perspectives of Mutant and Chimeric Plasminogen Activators (1992) (4)
- Biochemical and biological properties of single-chain urokinase-type plasminogen activator. (1986) (4)
- Thrombolytic therapy. (1991) (4)
- Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis. (1995) (4)
- A FUSION PROTEIN OF THE A-CHAIN OF t-PA WITH LOW Mr scu-PA COMBINES THE FIBRIN-SPECIFICITY OF BOTH MOLECULES (1987) (4)
- Purification and partial primary structure of cyanogen bromide fragments from human α2-antiplasmin (1982) (4)
- Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160. (1988) (3)
- Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. (1994) (3)
- Bio-Immunoassay for Staphylokinase in Blood (1993) (3)
- Inhibition in Purified Systems and in Human Plasma of Chimaeric Plasminogen Activators Consisting of the NH2-Terminal Region of Tissue-Type Plasminogen Activator and the COOH-Terminal Region of UrokinaseType Plasminogen Activator (1988) (3)
- Functional interactions between pancreatic beta cells and (pre)adipocytes (2010) (3)
- Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. (1992) (3)
- New thrombolytic agents and strategies. (1995) (3)
- [Tissue plasminogen activator: mechanism of action and thrombolytic properties]. (1986) (3)
- Modification of a tyrosine residue in the carboxyterminal portion of human alpha2-antiplasmin. (1985) (3)
- Chapter 8 Fibrinolysis and thrombolysis (1986) (2)
- Tissue-type plasminogen activator: helping patients with acute myocardial infarction (2001) (2)
- Correlation between progressive adsorption of plasminogen to blood clots immersed in a plasma milieu and clot sensitivity to lysis (1990) (2)
- Corrigendum to “Effect of premature ageing on murine adipose tissue” [Experimental Gerontology (2012) 256–262] (2012) (2)
- Functional Properties of p-Anisoylated Plasmin-Staphylokinase Complex (1993) (2)
- A SENSITIVE BIOINALNOASSAY (BIAS) FOR TISSUE PLASMINOGEN ACTIVATOR IN PLASMA: A REPLACEMENT FOR THE EUGLOBULIN CLOT LYSIS TIME (ECLT) ASSAY (1988) (2)
- Partial Primary Structure Of Human α2-Antiplasmin (1981) (2)
- Combination of animal models and biotechnologies in the development of new thrombolytic agents (1993) (2)
- Laboratory Investigation Thrombolytic andPharmacokinetic Properties ofaConjugate ofRecombinant Single-Chain Urokinase-Type Plasminogen Activator WithaMonoclonal Antibody Specific forCross-Linked Fibrin ina BaboonVenousThrombosis Model (1990) (2)
- PROPERTIES OF A HUMAN RECOMBINANT FUSION PROTEIN OF THE ‘FINGER’ DOMAIN OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) AND A TRUNCATED SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (scu-PA) (1987) (2)
- 282 Functional properties of chimaeric molecules containing structural domains of tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA) (1988) (2)
- Haemostasis (1997) (2)
- Basic Aspects of Fibrinolysis and Thrombolysis (2002) (1)
- Fibrinolytic properties of staphylokinase mutants obtained by ‘clustered charge-to-alanine’ mutagenesis* (1996) (1)
- Decreased Reactivity of Plasmin-Streptokinase Towards α-2-Antiplasmin (1979) (1)
- Characterisation of rt-PA I276G, a recombinant human tissue-type plasminogen activator mutant with altered plasmin cleavage site (1992) (1)
- Fibrin-specific Clot Lysis with Single Chain Urokinase-type Plasminogen Activator (scu-PA) (1990) (1)
- PROTEINASE INHIBITORS | Alpha-2 Antiplasmin (2006) (1)
- [Molecular mechanisms of thrombolytic therapy]. (1986) (1)
- Chromogenic substrate assays of components of the fibrinolytic system. (1982) (1)
- Amidolytic determination of Factor X in clinical plasma samples. (1983) (1)
- Extrinsic plasminogen activator: a new principle in fibrinolysis. (1983) (1)
- -Induced Abdominal Sepsis in Mice coli Escherichia Activator Is Protective during Endogenous Tissue-Type Plasminogen (2006) (1)
- The effect of retraction on the clot sensitivity to lysis (1990) (1)
- New strategies in the development of thrombolytic agents (1988) (1)
- Mechanism of action and thrombolytic potential of staphylokinase. (1995) (1)
- Plasminogen Activator Isoenzymes in Breast Tumours (1986) (0)
- Purification and partial primary structure of cyanogen bromide fragments from human alpha 2-antiplasmin. (1982) (0)
- Matrix Metalloproteinase-9 Deficiency Impairs Host Defense against Abdominal Sepsis 1 (2006) (0)
- infusion activator to fibrin: useful to monitor fibrinogen breakdown during t-PA A monoclonal antibody preventing binding of tissue-type plasminogen (2011) (0)
- Irish association for cancer research Proceedings of 23rd Annual Meeting held in Cork, May, 1966 (1987) (0)
- Saquinavir does not affect adipose tissue development or metabolic parameters in mice on high fat diet. (2006) (0)
- Subject Index, Vol. 16, Supplement 3, 1986 (1986) (0)
- Progress in the pharmacology of thrombolytic agents (1992) (0)
- Bernd Binder (January 7, 1945 – August 28, 2010) (2010) (0)
- CHARACTERIZATION OFα2-ANTIPLASMIN.REACTIVE SITE VARIANTS PRODUCED BY SITE-DIRECTED MUTAGENESIS (1987) (0)
- Vascular and cellular proteolytic activity in mice with α2-antiplasmin gene inactivation (2000) (0)
- Molecular Regulation of Fibrinolysis (1997) (0)
- Contents, Vol. 16, Supplement 3, 1986 (1986) (0)
- Fibrin(ogen) degradation by a 24k-endopeptidase from a Chryseobacterium Sp. (2000) (0)
- Fibrinolysis: Thrombolytic Agents, Mechanisms, and New Developments (1991) (0)
- Effect of Vioxx on adipose tissue development in mice with genetically determined obesity (2008) (0)
- Scientific and Standardization Committee Communications Recommendations for the Nomenclature of Mutant Fibrinolytic Genes and Their Proteins (1990) (0)
- plasma clot lysis with single-chain urokinase-type plasminogen activator in plasminogen activator. Application to the study of the mechanism of A monoclonal antibody specific for two-chain urokinase-type (2011) (0)
- Chromogenic substrate assays: mechanism, specificity and application in blood coagulation and fibrinolysis. (1983) (0)
- Mouse Genetic Models in Studying Adipose Angiogenesis (2013) (0)
- Biochemical and biological properties of a recombinant chimera consisting of amino acids Asn-1 to Lys-12 of α2-antiplasmin (fibrin cross-linking site) and amino aids Leu-4 to Leu-411 of single chain urokinase-type plasminogen activator (1992) (0)
- Welcome Address by Prof. A. Serradimigni (1986) (0)
- Plasmin-lnduced Platelet Activation and Disaggregation (2018) (0)
- Contributions of biotechnology to thrombolytic therapy (1992) (0)
- PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version (1998) (0)
- Biochemical, Thrombolytic and Pharmacokinetic Properties of rt-PA P47G, K49N, a Substitution Variant of Human Tissue-Type Plasminogen Activator (1992) (0)
- Contents Vol. 33 (2003) (0)
- Structure-function relationships in staphylokinase as revealed by “clusteredcharge-to-alanine” mutagenesis (1994) (0)
- Chapter 6 Explanations for coagulation activation after air travel (2009) (0)
- therapeutic potential? Staphylokinase, a fibrin-specific plasminogen activator with (2011) (0)
- [Mechanism of action of heparin]. (1986) (0)
- in a hamster pulmonary embolism model continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator Comparative thrombolytic properties of bolus injections and (2011) (0)
- Role of ADAMTS5 in non-alcoholic steatohepatitis (2018) (0)
- AN ALANINE INSERTION IN α2-ANTIPLASMIN ‘ENSCHEDE’ ABOLISHES ITS PLASM IN INHIBITORY ACTIVITY (1987) (0)
- Overexpression of PAI-1 Does Not Affect Adipose Tissue Development in Mice on SFD (2002) (0)
- mutant resistant to plasminogen activator inhibitor-1 recombinant human tissue-type plasminogen activator deletion Biochemical and biologic properties of rt-PA del ( K 296-G 302 ) (2003) (0)
- Extracellular proteolysis in development and progression of atherosclerosis (2002) (0)
- Pathophysiology of fibrinolysis (1994) (0)
- History of Discovery The Tissue-Type Plasminogen Activator Story (2009) (0)
- Intramolecular domain-domain interactions in tPA and tPA/Uk chimeric molecules (1994) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With H. Roger Lijnen?
H. Roger Lijnen is affiliated with the following schools: